Tumor Models Market Report 2025

The tumor model market size has grown rapidly in recent years. It will grow from $1.92 billion in 2024 to $2.13 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to the rising incidence of cancer, increasing demand for personalized medicine, the growing need for improved preclinical predictability, expanded use of patient-derived xenograft models, and a heightened reliance on in vivo efficacy data.

The tumor model market size is expected to see rapid growth in the next few years. It will grow to $3.23 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to an increasing focus on human-relevant models, rising demand for precision oncology, growth in immuno-oncology, expanding need for high-throughput screening models, and heightened interest in rare cancer models. Major trends in the forecast period include the development of three-dimensional (3D) cell culture models, advancements in pharmaceutical research and development, improvements in cell culture technologies, integration of AI in cancer modeling, and the development of patient-derived organoids.

The increasing demand for personalized medicine is expected to drive growth in the tumor models market in the coming years. Personalized medicine is a healthcare approach that leverages information about an individual’s genes and lifestyle to tailor treatments and care to their specific needs. This rising demand is fueled by people’s preference for health technologies that provide real-time monitoring and personalized treatment plans. Tumor models support personalized medicine by allowing researchers and clinicians to test and predict how a patient’s tumor will respond to specific therapies, serving as experimental platforms that mimic the behavior of real human cancers and enabling more targeted treatment strategies. For example, according to the Personalized Medicine Coalition, a US-based professional membership organization, the approval of 12 new personalized medicines in 2022 accounted for approximately 34% of all newly approved therapies, reflecting a substantial increase from previous years. Consequently, the growing demand for personalized medicine is driving the tumor models market.

Key players in the tumor models market are developing advanced solutions, such as tumor spheroid models, to improve the physiological relevance and predictive accuracy of in vitro cancer models. Tumor spheroid models are three-dimensional (3D) aggregates of cancer cells that naturally form spherical structures in culture. For instance, in June 2024, Predictive Oncology, a US-based provider of advanced 3D cell culture technologies and predictive oncology solutions, launched new 3D cell technology to accelerate cancer drug discovery. The platform offers advanced 3D tumor spheroid and organoid models that closely mimic the tumor microenvironment, high-throughput screening for rapid drug testing, support for patient-derived personalized tumor models, detailed analysis of drug penetration in 3D structures, and integration with AI-driven data analytics to enhance predictive accuracy and provide deeper insights into therapeutic responses.

In October 2024, Merck & Co. Inc., a US-based pharmaceutical company, acquired Modifi Biosciences for an undisclosed amount. Through this acquisition, Merck aims to strengthen its oncology portfolio by incorporating Modifi’s novel small-molecule therapies, which selectively target cancer cells with DNA repair deficiencies, particularly in hard-to-treat tumors such as glioblastomas. Modifi Biosciences Inc., based in the US, specializes in tumor models.

Major players in the tumor models market are Merck & Co Inc., LabCorp Holdings Inc., Eurofins Scientific SE, WuXi AppTec Co Ltd., Charles River Laboratories International Inc., PerkinElmer Inc., Pharmaron Beijing Co. Ltd., The Jackson Laboratory, Taconic Biosciences Inc., Cyagen Biosciences Inc., Crown Bioscience Inc., Champions Oncology Inc., Reaction Biology Corporation, InSphero AG, Creative Biolabs Inc., Oncodesign S.A., Xentech S.A., MIMETAS BV, Experimental Pharmacology and Oncology Berlin-Buch GmbH, and Hera BioLabs Inc.

North America was the largest region in the tumor models market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tumor models market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the tumor models market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Tumor models are experimental biological systems designed to replicate the characteristics and behavior of tumors in living organisms. They aim to mimic the cellular makeup, molecular features, growth patterns, and interactions with the surrounding environment. These models enable researchers to study tumor development and progression under controlled conditions, facilitating a deeper understanding of cancer biology.

The primary types of tumor models include primary tumor models, metastatic tumor models, orthotopic tumor models, and heterotopic tumor models. Primary tumor models are experimental tumors created by implanting or inducing cancer cells at the site where the tumor naturally originates. These models are applied in drug discovery and development, cancer research, personalized medicine, and toxicology studies. Various technologies are employed, including xenograft models, genetically engineered mouse models (GEMMs), three-dimensional (3D) tumor spheroids, and organ-on-a-chip systems. End users include pharmaceutical and biotechnology companies, academic institutions, contract research organizations (CROs), and government research organizations.

The tumor models market research report is one of a series of new reports that provides tumor models market statistics, including tumor models industry global market size, regional shares, competitors with a tumor models market share, tumor models market segments, market trends and opportunities, and any further data you may need to thrive in the tumor models industry. This tumor models market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tumor models market includes revenues earned by entities by providing services such as drug screening and efficacy testing, tumor biology research, biomarker discovery and validation, toxicology and safety testing, and immuno-oncology studies. The market value includes the value of related goods sold by the service provider or included within the service offering. The tumor models market also includes sales of cancer cell lines, in vitro tumor models, imaging systems, tumor model kits, and reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.